3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Magnetic Resonance Spectroscopy
13
gallium 68 PSMA-11
8
Fluorodeoxyglucose F18
5
Specimen Handling
4
Positron Emission Tomography Computed Tomography
4
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
4
enzalutamide
3
Nivolumab
3
Ipilimumab
3
Interleukin-2
3
Biopsy
3
68Ga-DKFZ-PSMA-11
3
pembrolizumab
2
pazopanib
2
lenvatinib
2
bicalutamide
2
atezolizumab
2
aldesleukin
2
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
X-Rays
2
Standard of Care
2
Radiation
2
Positron-Emission Tomography
2
Paclitaxel
2
Oncolytic Virotherapy
2
Nephrectomy
2
Metformin
2
Metastasectomy
2
Immunoglobulin G
2
Hydroxychloroquine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Aminophylline
×
Genitourinary
×
Clear all
NCT01240824
2014-04-14
BCG
University of Virginia
Phase EARLY_PHASE1
Completed
3 enrolled